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This Perspective reviews recent findings in placebo hypoalgesia and provides a conceptual account of how
expectations and experience can lead to placebo hypoalgesia. In particular, we put forward the idea that the
ascending and the descending pain system resembles a recurrent system that allows for the implementation
of predictive coding—meaning that the brain is not passively waiting for nociceptive stimuli to impinge on it
but is actively making inferences based on prior experience and expectations. The Bayesian formulation
within the predictive coding framework can directly account for differences in the magnitude but also the
precision of expectations that are known to influence the strength of placebo hypoalgesia. We discuss
how modulatory neurotransmitters such as opioids might be related to the characterization of expectations
with an emphasis on the precision of these expectations. Finally, we develop experimental strategies that are
suited to test this framework at the behavioral and neuronal level.Introduction
Placebo effects are a powerful illustration of the strong influence
that expectations can have on treatment outcome and have
therefore received enormous attention over the last decade,
resulting in many comprehensive reviews on placebo effects in
general (Benedetti, 2013; Colloca and Benedetti, 2005; Enck
et al., 2013; Oken, 2008; Price et al., 2008), placebo hypoalgesia
in particular (Carlino et al., 2011; Colloca and Benedetti, 2005;
Kong et al., 2007), and the possible neurobiological mechanisms
underlying placebo hypoalgesia (Tracey, 2010; Wager and
Fields, 2013). Importantly, expectancy effects are not limited to
inert (placebo) treatments but can significantly affect the behav-
ioral and neural outcome of real treatments (Bingel et al., 2011;
Schenk et al., 2014; but see Atlas et al., 2012). Although most
authors speak of placebo analgesia, the term seems technically
incorrect as most placebo effects in the domain of pain lead to a
decreased pain sensation (i.e., hypoalgesia) and not to the
absence of pain (i.e., analgesia). We will thus use the term
placebo hypoalgesia throughout this article.
This Perspective reviews the neurobiology of placebo hypoal-
gesia, as this is the field of placebo mechanisms in which most
neurobiological data is available. Placebo effects in the context
of pain have been intensively studied using functional neuroi-
maging (for a recent meta-analysis, see Amanzio et al., 2013).
fMRI studies in healthy volunteers have revealed contributions
of spinal (Eippert et al., 2009a; Geuter and Bu¨chel, 2013) and
supraspinal (Bingel et al., 2006; Eippert et al., 2009b; Ellingsen
et al., 2013; Kong et al., 2006; Lu et al., 2010; Lui et al., 2010;
Petrovic et al., 2002; Wager et al., 2004; Watson et al., 2009)
areas to placebo-induced pain modulation in healthy volunteers.
Furthermore, combining these imaging approaches with phar-
macological challenges (Eippert et al., 2009b), as well as using
molecular imaging techniques based on positron emission
tomography (PET) (Pecin˜a et al., 2013; Scott et al., 2007, 2008;
Wager et al., 2007; Zubieta et al., 2005), revealed information
about the involvement of different neurotransmitter systems.Information on the temporal aspects of these effects has been
gained by studies using electroencephalogram (Colloca et al.,
2008; Watson et al., 2007). Taken together, these studies have
provided evidence for a very early hypothesis (Levine et al.,
1978), namely that placebo hypoalgesia recruits an opioidergic
system of descending pain control (Bee and Dickenson, 2009;
Ren and Dubner, 2009), the activation of which leads to inhibition
of nociceptive processing at the level of the spinal cord and thus
reduces neural responses in pain-responsive brain regions as
well as the experience of pain.
A Conceptual Framework for Placebo Hypoalgesia
In the following, we will take this idea further and propose that a
hierarchical Bayesian framework of brain function based on the
idea of predictive coding (Jehee and Ballard, 2009; Rao and
Ballard, 1999; Srinivasan et al., 1982) can account for many
facets of placebo hypoalgesia. In essence, we suggest that
placebo hypoalgesia is the result of combining top-down prior
expectations or predictions of pain (relief) with bottom-up
sensory signals at multiple levels of the neural hierarchy.
An important aspect of this framework is that not only the
mean of the predictions and sensory signals but also their preci-
sion (i.e., inverse variance) is important. We will show that recent
findings in placebo hypoalgesia are in agreement with such a
framework and furthermore suggest a possible neuronal imple-
mentation. Although the precise nature and implementation of
the model in neurobiological terms must remain speculative at
this time, the model as outlined below generates testable
hypotheses for future studies on placebo hypoalgesia.
While the proposed framework will be applicable to placebo
effects in other domains than pain, we focus on placebo hypoal-
gesia, because of the extensive literature on effect sizes (Vase
et al., 2002, 2009) and neurobiological mechanisms (Colloca
and Benedetti, 2005; Tracey, 2010; Wager and Fields, 2013). It
is important to note at the outset that we are only considering
acute pain in the healthy state and for now leave aside the impli-
cations of this framework for chronic pain states.Neuron 81, March 19, 2014 ª2014 Elsevier Inc. 1223
Figure 1. The Effect of Precision of Prior
Expectations for Placebo Hypoalgesia
Based on Pollo et al. (2001). The blue distribution
characterizes the incoming sensory data
(observation/likelihood); the red distribution char-
acterizes the expectation (prior). Integrating this
information in a Bayesian fashion leads to the
posterior distribution (green) that resembles the
effect of the placebo manipulation (for simplicity,
we plot estimated perceived pain intensity,
whereas in the original study the placebo effect
size was estimated by required medication). In the
control condition (A), no expectation is generated,
and a (flat) prior is centered on the mean of the
stimulus. Consequently, the perceived pain
(green) is identical to the stimulus (blue, hidden).
Telling volunteers that they either perceive drug or
placebo creates a more variable prediction (red
distribution in B) as compared to an instruction in
which volunteers are told that they will definitely
get the drug (red distribution in C), which conse-
quently leads to a stronger placebo effect (green
distribution shifted further toward less painful VAS
ratings). Note that in (B), a second prior (red)
centered on VAS 60 could have been modeled to
account for the fact that 50% of the patients
received no treatment. Note that this figure is only
an illustrative example and does not represent




In information processing, it is useful to integrate new incoming
information with already existing knowledge or expectations.
For example, if a volunteer expects pain on a visual analog scale
(VAS) around 40 (Figure 1), Bayes theorem can be used to esti-
mate the level of perceived pain, taking prior knowledge into
account (see O’Reilly et al., 2012 for an intuitive introduction).
A Bayesian system estimates the posterior probability of the
perceived pain, given an observation and a prior (expectation):
pðpainjsensory inputÞfpðpainÞpðsensory inputjpainÞ
(Equation 1)
In other words, the posterior probability p(painjsensory input)
is proportional to the product of the prior probability p(pain)
and the likelihood of p(sensory inputjpain).
Contemporary theories of brain function employ this
Bayesian idea and suggest that neuronal assemblies imple-
ment perception and learning by constantly matching incoming
sensory data with the top-down predictions of an internal or
generative model (Clark, 2013; Huang and Rao, 2011; Knill
and Pouget, 2004). This is known as predictive coding and
the model is called generative because top-down predictions
are generated by a hierarchical model whose variables and
parameters are optimized on different timescales. In other
words, the brain has a model of the world that it continuously
tries to optimize using sensory inputs (Friston, 2010). Initially,
this model is defined by various genetic and epigenetic factors
(Clark, 2013; Friston et al., 1994), which are then continuously
refined over the lifespan through associative plasticity and
neurodevelopmental learning. This enables more efficient pre-1224 Neuron 81, March 19, 2014 ª2014 Elsevier Inc.diction as the brain learns the causal structure and regularities
underlying sensations.
A key element of this framework is the mismatch between
descending predictions and ascending sensory signals, which
can be seen as a prediction error reporting the ‘‘surprising’’
(because it was not predicted) aspect of the sensory information.
This part of the signal is forwarded to higher areas to adjust the
predictions (for perceptual inference) and parameters (for
perceptual learning), which in turn minimizes prediction errors.
Another important aspect of predictive coding is its Bayesian
formulation that allows incoming data to be considered in the
context of prior knowledge. These prior beliefs are entailed by
the descending predictions. Importantly, both prior beliefs and
sensory evidence are represented in terms of probability density
functions. This is important because it means the brain has to
encode the uncertainty about sensory signals (and prior predic-
tions) in terms of their precision. Precision is the confidence or
inverse variance of a probability distribution. The problem of
how priors are specified de novo is circumvented by the hierar-
chical nature of the generative model, in which the posterior
beliefs at any level of the hierarchy constitute (empirical) prior
beliefs for the level below. This is formally identical to the empir-
ical Bayes framework in statistics in which priors are estimated
from the data (Efron, 2009). An important aspect of predictive
coding—from the current perspective—is that both the content
of sensory input and its context have to be predicted. This man-
dates descending predictions of both the incoming sensory sig-
nals and their precision. The balance of sensory evidence,
against descending empirical prior beliefs, is controlled by the
precision at the respective levels of the hierarchy. In biological
implementations of predictive coding, precision is thought to
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ing prediction errors.
Predictive coding can be considered as a consequence of the
free-energy principle (Friston, 2010). The free-energy principle
states that self-organizing systems that are in a homeostatic
state must minimize their free energy (i.e., resist the natural
tendency to increase their disorder or entropy). In this formula-
tion, minimizing prediction errors lead to better models that allow
the system to resist their tendency to disorder by being good
predictors of the sensory environment. This theory goes beyond
predictive coding, as it explicitly incorporates actions as a mean
of minimizing prediction errors.
Although experimental data supporting such a framework
have mostly been observed in the visual system (Egner et al.,
2010; Hesselmann et al., 2010; Knill and Pouget, 2004; Rao
and Ballard, 1999; Sterzer et al., 2008; Summerfield et al.,
2006), there is growing support for the role of such a framework
in explaining, for example, auditory (Moran et al., 2013; Todor-
ovic et al., 2011) and interoceptive (Seth et al., 2011) responses.
Furthermore, predictive coding and active inference has been
employed to account for various neuropsychiatric disorders
and symptoms such as functional motor and sensory symptoms
(FMSSs) (Edwards et al., 2012), delusions (Schmack et al., 2013),
hallucinations in psychosis (Adams et al., 2013; Corlett et al.,
2009), and disorders of agency (Seth et al., 2011). With respect
to FMSS, Edwards and colleagues (2012) suggested that abnor-
mally ‘‘precise’’ expectations can be the basis of pain in these
patients, in analogy to the notion that abnormal assignment of
salience to nociceptive input (Borsook et al., 2013) might
contribute to the formation of chronic pain. Crucially, all of these
accounts focus on the optimization of the precision or confi-
dence afforded to prediction errors at sensory and higher hierar-
chical levels. Last but not least, even processes in the social
domain have been framed in terms of predictive coding (Brown
and Bru¨ne, 2012; Koster-Hale and Saxe, 2013; see also Krahe´
et al., 2013 for a perspective on the interplay of social factors
and pain). As predictive coding accounts have been successful
in explaining neuronal responses at retinal (Srinivasan et al.,
1982), thalamic (Jehee and Ballard, 2009), and cortical levels
(Rao and Ballard, 1999), one could expect that predictive coding
is a general strategy employed by the CNS and thus applicable
to pain as well (Seymour and Dolan, 2013).
The nociceptive system originates in the body periphery, from
where primary afferent nociceptors transmit signals to the dorsal
horn of the spinal cord, where they activate second-order
neurons that project to supraspinal structures. These ‘‘bottom-
up’’ pathways are numerous (with the spinothalamic tract being
the most prominent one), and axons terminate, for example, in
brainstem, midbrain, and diencephalic regions such as the
rostral ventromedial medulla (RVM), the noradrenergic cell
groups, the parabrachial area, the periaqueductal gray (PAG),
the amygdala (AMY), the hypothalamus (HT), and the thalamus
(THA) (Dostrovsky and Craig, 2013; Lima, 2009). From here,
higher-order neurons project to various medial and lateral
cortical regions that are thought to mediate different aspects of
pain (Tracey and Mantyh, 2007).
This ascending (‘‘bottom-up’’) system is complemented by a
descending (‘‘top-down’’) system that can exert both inhibitoryand facilitatory influences (Bee and Dickenson, 2009; Heinricher
and Fields, 2013; Ren and Dubner, 2009; for the sake of brevity
we are simplifying anatomical matters here, as there are other
routes of descending control, for example, via noradrenergic
cell groups). It originates in cortical areas, including the rostral
anterior cingulate cortex (rACC) and anterior insula (AI), and
projects—via subcortical regions such as the AMY and HT—to
the PAG. The PAG in turn sends massive projections to the
RVM (Basbaum and Fields, 1984), which modulates signal trans-
mission at the dorsal horn of the spinal cord.
We propose that it is possible to reframe the dichotomy of
ascending versus descending systems in terms of a recurrent
system as it is required for a predictive coding framework (Fris-
ton, 2010; Mumford, 1992). First, in line with the principle of reci-
procity of corticocortical connections (Felleman and Van Essen,
1991), the above-mentioned areas are not connected in a unidi-
rectional fashion, as for example the term ‘‘descending system’’
suggests: for example, the rACC to PAG to RVM pathway also
contains reciprocal connections (i.e., RVM to PAG to rACC;
Beitz, 1982a; Herrero et al., 1991). Second, the involvement of
the primary neuromodulators for pain—endogenous opioids—
is not only evident in the classic PAG to RVM to spinal cord
pathway but in nearly all regions of both the descending and
ascending systems (with the notable exception of primary
somatosensory cortex; Baumga¨rtner et al., 2006; Zubieta
et al., 2001). Third, cortical regions such as the AI and dorsal
ACC that often show placebo-induced decreases in response
to pain (Amanzio et al., 2013; Wager and Fields, 2013) are also
involved in modulatory functions (Eippert and Buchel, 2013).
Finally, even the most central element of descending control—
the PAG—is strongly responsive to nociceptive stimulation and
involved in ascending relay of nociceptive information, as evi-
denced by both fMRI (Ritter et al., 2013) and electrophysiological
data (Johansen et al., 2010). Taken together, this suggests that a
classification of brain areas into ‘‘pain responsive’’ (as part of
the ascending system) and ‘‘pain modulatory’’ (as part of the
descending system) might be too simplistic and obscures the
‘‘reciprocal nature of many interconnecting pathways’’ (Millan,
2002).
Precision Matters
Many neuroimaging studies have modulated the magnitude of
expected pain in nonplacebo contexts (Atlas et al., 2010; Keltner
et al., 2006; Koyama et al., 2005; Lorenz et al., 2005; Yoshida
et al., 2013) and can show that perceived pain intensity and
concomitant neural responses are influenced by cue informa-
tion. Lorenz and colleagues (2005) used two different pain inten-
sities and cued them by different tones. They observed that the
cue influenced pain perception such that high-intensity stimuli
were perceived as less painful and low-intensity stimuli as
more painful following invalid compared to valid cues. However,
an expectation is not only characterized by its magnitude but
also by its precision or certainty. This was studied by Brown
and colleagues (2008), who employed different pain intensities
with either certain or uncertain expectations. In agreement with
Bayesian integration, they observed that high-intensity painful
stimuli were perceived as more painful with a ‘‘certain’’ expecta-
tion, whereas low-intensity painful stimuli were perceived as less
painful in the context of the ‘‘certain’’ expectation. A recent studyNeuron 81, March 19, 2014 ª2014 Elsevier Inc. 1225
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perceived pain intensities (Yoshida et al., 2013) also reported
that a Bayesian model outperformed a mean model; however,
in contrast to Brown and colleagues (2008), they observed that
uncertainty increased perceived pain for the high-intensity pain
stimulus, which might be related to the vicariously observed
mean and uncertainty of the pain stimulus.
Apart from cue-based pain studies, Bayesian integration can
also be observed in placebo hypoalgesia. Pollo and colleagues
(2001) demonstrated that different levels of precision of verbal
instructions about the analgesic effect of a treatment can pro-
duce different placebo effect sizes (Figure 1). The more precise
instruction telling patients that the infusion contains a potent
painkiller led to a more pronounced placebo effect as the less
precise instruction in which volunteers were told that the infusion
was either a powerful painkiller or a placebo.
A similar effect of variability of the instructions was observed in
irritable bowel syndrome (IBS) patients who were exposed to
clinically relevant abdominal pain by means of rectal balloon
distension under different expectation conditions. In one study,
patients were told, ‘‘this may be an active agent or an inactive
placebo agent’’ (Verne et al., 2003). In another one they were
told that ‘‘the agent you have just received is known to sig-
nificantly reduce pain in some patients’’ (Vase et al., 2003). As
the second suggestion created a more precise expectation,
the observed placebo analgesic effect was larger in this study.
These examples illustrate that the effect size of placebo
responses can be maximized by the magnitude and the preci-
sion of the prior expectation.
The Site of Modulation
Pain is a psychologically constructed experience that includes
extensive processing at the cortical level (Apkarian et al., 2005;
Tracey and Mantyh, 2007). A mechanism subserving placebo
hypoalgesia could therefore theoretically be implemented at
the cortical or subcortical level. In agreement with this idea, initial
studies on placebo hypoalgesia firmly established the involve-
ment of the rACC and prefrontal cortex (PFC) with projections
to the PAG in placebo hypoalgesia (Bingel et al., 2006; Petrovic
et al., 2002; Wager et al., 2004). These early studies supported
the view that ‘‘a major portion of the placebo effect may bemedi-
ated centrally by changes in specific pain regions’’ (Wager et al.,
2004). However, several years later, a series of placebo hypoal-
gesia experiments demonstrated effects in relation to placebo
hypoalgesia in the medulla (Eippert et al., 2009b; note that
Petrovic and colleagues, 2002 already observed placebo-
related signal changes in an area close to the RVM) and even
at the spinal cord level (Eippert et al., 2009a; Matre et al.,
2006). These observations speak against a model in which
placebo hypoalgesia is an exclusively supraspinal phenomenon,
but rather suggest that placebo hypoalgesia is implemented
through a hierarchical recurrent system including cortical
(rACC and AI), subcortical (AMY, HT, and THA), midbrain
(PAG), medulla (RVM), and spinal sites. This is reminiscent of
the visual system, in which a recurrent hierarchical system
including the retina, the lateral geniculate nucleus, primary visual
cortex, and higher-order visual areas are likely to implement a
predictive coding framework for visual perception (Jehee and
Ballard, 2009; Rao and Ballard, 1999; Srinivasan et al., 1982).1226 Neuron 81, March 19, 2014 ª2014 Elsevier Inc.The Generation of Expectations: Learning and
Experience
The placebo effect is based on expectation and experience,
where the latter is a form of learning and often implemented by
conditioning in experimental placebo studies. After a debate
about the importance of each factor (Stewart-Williams and
Podd, 2004), there seems to be agreement that both can be
important contributors to the placebo effect.
The proposed framework suggests that expectations (i.e.,
predictions) are the consequence of experience (i.e., parameters
of the internal model). This is best exemplified in the context of
conditioning in placebo hypoalgesia (Colloca and Benedetti,
2006; Stewart-Williams and Podd, 2004). Through the pairing
of an analgesic treatment (e.g., analgesic drug or simply reduc-
tion of the afferent painful stimulus) with a sensory cue (e.g., the
visual and tactile information that a ‘‘treated’’ skin patch is stim-
ulated), an expectation of hypoalgesia is formed (Meissner et al.,
2011) and consequently the parameters of the internal model are
updated to account for this effect.
In a series of studies, the role of conditioning (Colloca and
Benedetti, 2006; Colloca et al., 2010) has been investigated.
During the conditioning phase of the first study, Colloca and
Benedetti (2006) observed pain ratings for the cued treatment
at a level of about 1 (due to a reduction of stimulus intensity),
whereas the cued pain trials scored 6 on their scale (i.e., a
‘‘treatment’’-related difference of 5 between both cues). In the
following test block with equal stimulus intensities, they
observed a significant placebo hypoalgesic effect indicated by
a difference between both cues of 3.5. In the presented frame-
work, the perceived level of pain during the test phase (around
3.5) represents the combination of prior expectation (about 1)
and the incoming sensory information (around 6). What is
observed is the posterior, i.e., the statistically optimal combina-
tion of the prior information and the incoming sensory data.
Although the authors observed no within block extinction, after
4–7 days the placebo hypoalgesic effect was reduced (i.e., a
difference of 2 between both cues), which according to our
model resembles either the loss of precision or a decrease in
magnitude of the prior information, both of which result in a
percept that is closer to the incoming data. This might be related
to the observation of Harrison and colleagues (2006) showing
uncertainty encoding in the hippocampus, a memory-related
structure involved in placebo hypoalgesia (Pecin˜a et al., 2013).
In a later study, Colloca and colleagues (2010) were able to
show that four conditioning trials lead to stronger placebo effect
as compared to a single conditioning trial. In addition, volunteers
who received a single conditioning trial showed more rapid
extinction compared to the group receiving four conditioning
trials. Importantly, the reduction of stimulus intensity during the
conditioning phase was identical in both groups. Therefore, the
only difference between groups was the amount of precision
that volunteers assign to the conditioning phase. Thus, in agree-
ment with our model, the group receiving four conditioning trials
forms a more precise prior expectation and thus shows the
stronger placebo hypoalgesic effect.
Finally, the role of experience for placebo effects has also
been established in a more clinically oriented context (Kessner
et al., 2013a). In this study, the effect of previous treatment
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agreement with the view that positive experience with previous
treatment generates predictions on treatment success in the
current setting, the authors observed a strong positive effect of
prior experience, i.e., previous successful treatment predicted
current treatment success. This observation illustrates that the
important concept of a hierarchical model in which data are
used to generate priors is also present in the time domain, or
in simpler words, a past posterior can be used as a current prior.
The Limits of Placebo Hypoalgesia and Individual
Differences
In agreement with the predictive coding framework Crombez
and Wiech (2011) argued that expectations can bias perception
but sensory evidence can also update expectations. According
to our model, the placebo hypoalgesic effect is caused by
matching a predictive model with incoming data by explaining
away the discrepancy (i.e., prediction error). It is now interesting
to speculate what would happen if the incoming sensory data is
‘‘too far away’’ from the current model. This would be the case
when during conditioning an expectation of placebo hypoalgesia
was generated with a very low-intensity stimulus and subse-
quently during the test phase a very high-intensity stimulus
was used. In these cases, volunteers might question the efficacy
of the treatment and as a consequence generate a disbelief in the
placebo treatment. In our suggested model, this phenomenon
resembles a dramatic revisiting of the model to explain the
incoming data, i.e., the initial model of ‘‘a real treatment reducing
pain’’ might be replaced by a model that entails a deception and
that no treatment has been applied. This model would thus
dramatically reduce the prediction error. This can be seen in
analogy to shifts in explanatory models that are thought to
underlie the perceptual dynamics in binocular rivalry (Clark,
2013; Hohwy et al., 2008) or viewing of ambiguous figures
such as the face-vase illusion (Kleinschmidt et al., 1998), in which
competing percepts can partially satisfy two different models
(one for each stimulus). However, as the system has not been
exposed to this rather artificial situation, each model leaves a
considerable prediction error, resulting in switches between
percepts.
A breakdown of placebo hypoalgesia can also be anticipated
from a different perspective in the predictive coding scheme:
simulations in the visual system have shown that elimination of
prediction signals from higher areas leads to a breakdown of
the ‘‘explaining-away’’ component of prediction errors in lower
areas (Rao and Ballard, 1999). It is thus tempting to explain
recent finding in placebo hypoalgesia in this light: a diminished
function of the PFC (as found under repetitive transcranial
magnetic stimulation (Krummenacher et al., 2010) or in
Alzheimer’s disease (Benedetti et al., 2006a) has been shown
to lead to a loss of placebo hypoalgesic effects. Along these
lines, the structural integrity of white matter pathways from
PFC to lower areas has been shown to be related to placebo hy-
poalgesia (Stein et al., 2012). Together, these data suggest that a
failure of downward message passing of predictions from a
higher area will lead to exacerbated prediction errors and thus
a higher influence of sensory signals, i.e., a higher level of pain.
In some studies, the authors have demonstrated placebo
effects when telling participants explicitly that they will receivea placebo (Kaptchuk et al., 2010). The authors told volunteers
explicitly about the effectiveness of placebo and thus created
a treatment expectation. However, as this study took place in
a clinical environment, it is highly likely that volunteers also
created an expectation based on experience with this environ-
ment, which would interact with the placebo treatment. Most
people associate hospitals with effective medical treatment
and symptom reduction and thus a covert expectation of pain
relief might have been generated. In agreement with the sugges-
tion that unconscious expectations can drive placebo hypoalge-
sia, a recent study from this group showed that nonconscious
cues are indeed sufficient to trigger pain modulation (Jensen
et al., 2012). A similar, implicit expectation is seen in studies
investigating classical conditioning in which volunteers generate
predictions and prediction errors but are not aware of the expec-
tation (i.e., pairing of sensory stimulus with shock) (Morris et al.,
2001).
Placebo effects in general vary across and within individuals
(Atlas andWager, 2012). Early studies (Levine et al., 1978) report
that around one-third of all volunteers showed a placebo hypo-
algesia effect. This rate is similar in recent studies (Benedetti,
1996; Bingel et al., 2006; Price et al., 2008). Interestingly, it has
been observed that although volunteers differ in their individual
placebo effects for different contexts (Liberman, 1964), they
show stable responses when repeatedly tested in these contexts
(Atlas and Wager, 2012; Whalley et al., 2008). This is easily inte-
grated in the predictive coding model: volunteers will have
formed a specific model for different contexts. If repeated treat-
ments provided by Doctor X were beneficial, the generated
model will predict a successful treatment by Doctor X in the
future. However, this does not necessarily involve the same
model in other patients in which the experience with Doctor X
was either less positive or variable (Kessner et al., 2013a). How-
ever, it is important to note that the model is not necessarily sta-
ble, as over time the organism will receive additional information
either directly linked to this context (e.g., newspaper report that
Doctor X is involved in a malpractice suit) or indirectly (e.g.,
newspaper reports on bad performance by doctors in general).
It is therefore not surprising that the test-retest correlation for
placebo is not higher than R2 = 0.55 (Morton et al., 2009).
The Role of the PAG-RVM-Spinal Pathway and Opioids
The common assumption about the role of opioids is that
placebo hypoalgesia is paralleled by a release of endogenous
opioids and that these are responsible for the perceived pain
reduction by acting as endogenous analgesics. This hypothesis
is supported by data showing that opioid antagonists can at least
partially block placebo hypoalgesia (Benedetti et al., 1999;
Eippert et al., 2009b).
However, another mechanism is suggested by studies inves-
tigating conditioned analgesia (Bolles and Fanselow, 1982; Fan-
selow, 1986). In classical conditioning, the conditioned stimulus
(CS, usually a neutral sensory cue) that is repeatedly paired with
a unconditioned stimulus (US, usually a painful shock) comes to
predict the shock and also elicits the release of endogenous
opioids. Initially, it was thought that the release of endogenous
opiods decreases the discrepancy (i.e., prediction error)
between the expectation generated by the CS and the painful
US by reducing the impact of the pain of the US throughNeuron 81, March 19, 2014 ª2014 Elsevier Inc. 1227
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prediction errors drive learning in a delta rule learning model
(Rescorla and Wagner, 1972), the application of the opiate
antagonist naloxone can block this effect and facilitate learning
(Eippert et al., 2008; McNally et al., 2004a, 2011). However, for
this mechanism to be universally correct, naloxone should
have no effect on procedures in which there is no US present
and thus its impact cannot be modulated (neither by endoge-
nous opioids nor by naloxone). Yet this is not the case, as exper-
imental data clearly show that endogenous opioids interfere with
second-order fear conditioning (Cicala et al., 1990) and that
naloxone reduces extinction (McNally et al., 2004b), i.e., showing
exactly the opposite effect as in conditioning. To reconcile these
data with a delta rule learning model (Rescorla and Wagner,
1972), a viable alternative explanation is that opioidergic neuro-
transmission is involved in modulating the prediction (i.e., the
CS) rather than affecting the outcome alone (i.e., the US)
(McNally et al., 2004b).
In agreement with these observations from classical condi-
tioning, we propose that in addition to a direct analgesic effect
(as for example exerted on synaptic terminals of nociceptive
afferents in the dorsal horn), opioids play an additional role in
signaling top-down predictions in a generative model, namely
representing the precision of the top-down prediction (or the pre-
cision-weighted prediction errors) in the PAG-RVM-spinal cord
system. This is also in agreement with an earlier notion that the
role of opioids is to ‘‘gate’’ sensory information (Bolles and Fan-
selow, 1982; Lewis et al., 1981).
The final segments of the descending pain modulatory system
comprise the PAG, RVM, and the spinal cord dorsal horn. The
RVM (as well as the PAG) is characterized by distinctive cells
(Fields et al., 1983; Heinricher et al., 1987) that show a pause
of firing (Off cells) or a burst of firing (On cells) just before a noci-
ceptive withdrawal reflex occurs in the anesthetized animal
(Fields, 2004; but see Mason, 2012). Other cells show a neutral
behavior, but it has been shown that this allocation is dynamic
as neutral cells can become On cells in certain circumstances
(Bee and Dickenson, 2009). Both On and Off cells can be modu-
lated by opioids, but it is the activation of Off cells that is critical
for opioid-mediated analgesia (Heinricher et al., 1994). In case of
Off cells, a presynaptic opioidergic inhibition of GABAergic pro-
jections explains the activation of Off cells by opioids. In
contrast, On cells are directly inhibited by morphine through a
postsynaptic opioidergic effect. Consequently, opioid agonists
activate Off cells (and silence On cells) and this effect leads to
analgesia as indicated by reducedwithdrawal responses. Impor-
tantly, the effect of morphine on Off cells can be blocked by an
NMDA antagonist (Heinricher et al., 2001). The projections
from the RVM to the dorsal horn are mainly GABAergic, glyciner-
gic, and serotonergic (Aicher et al., 2012; Kato et al., 2006;
Ossipov et al., 2010), but a clear assignment of these neurotrans-
mitters to the On or Off system is lacking and possibly nonexis-
tent (Gao andMason, 2000; Morgan et al., 2008; Pedersen et al.,
2011). Similarly, the effects on spinal processing do not follow an
all-or-none regime but are very specific in terms of inhibition of
noxious versus innocuous responses, deep versus superficial
laminae, and type of afferent fiber (for review, see Heinricher
et al., 2009). It is also interesting to note that cholecystokinin1228 Neuron 81, March 19, 2014 ª2014 Elsevier Inc.(CCK), which is often portrayed as an antiopioid and whose
actions underlie nocebo hyperalgesia (Benedetti et al., 2006b),
acts in this RVM-spinal circuit, also in combinationwith serotonin
(Dogrul et al., 2009; Marshall et al., 2012). Most placebo hypoal-
gesia studies have investigated brain activity changes with
respect to pain modulation shortly before (i.e., anticipation) or
during the application of the painful stimuli. This seems to be
at odds with the initial observations of tonic activations of the
On-Off cell system. However, recent studies in awake animals
(Mason, 2012) have revised this picture and indicate a more
phasic response profile of this system, which might explain
why fMRI studies investigating evoked responses are able to
observe activations related to pain modulation.
Bayesian models including predictive coding and the free-
energy principle not only rely on a representation of the magni-
tude of the prediction but also on its precision or variance. It
has been suggested that feedback signaling in the hierarchy
through NMDA is responsible for the specification of the priors
(or predictions) (Corlett et al., 2009; Friston, 2010) and that the
precision of these predictions is implemented through modula-
tory neurotransmitters (Corlett et al., 2009; Edwards et al.,
2012; Friston, 2010). Extending these ideas to placebo hypoal-
gesia, we suggest that the NMDA part of the Off cell system
could represent the prior or prediction signal and that the opioi-
dergic component of this system represents the precision of this
prediction. Currently, this notion is obviously speculative, but
future studies investigating opioidergic effects (either using
PET or pharmacological challenges) in combination with an inde-
pendent manipulation of the magnitude and the precision of the
top-down prediction (i.e., experimental manipulation of placebo
hypoalgesia) could test this hypothesis.
A possible mechanism by which placebo hypoalgesia could
be implementedwas already introduced 50 years ago inMelzack
andWall’s gate control theory (1965). As this mechanism posited
a crucial modulatory stage at the spinal cord, its involvement in
placebo hypoalgesia was questioned for a long time, as no spinal
involvement in placebo hypoalgesia had been observed until a
few years ago (Eippert et al., 2009a; Matre et al., 2006). While
it is important to note that originally this model was intended to
explain local control through large- and small-diameter fibers
at the spinal cord (Melzack and Wall, 1965), the authors also
postulated a ‘‘central control trigger’’ i.e., a fast afferent system,
which would precede the ordinary signal processing route and
could thus ‘‘set the receptivity of cortical neurons for subsequent
afferent volleys’’ and ‘‘by way of central-control efferent fibers,
also act on the gate control system’’ (Melzack and Wall, 1965).
Through this putative mechanism ‘‘it is possible for central
nervous system activities subserving attention, emotion, and
memories of prior experience to exert control over the sensory
input.’’ Although this model has shown great explanatory power,
it seems important to add a few details that make this theory
compatible with a full hierarchical predictive coding model. The
main point of a predictive coding model is the hierarchical orga-
nization in which prior information can be estimated from the
data at each level. Taking the original authors’ suggestion that
interactions take place at many levels (Melzack and Wall,
1965), we propose that instead of a single modulatory effect at
the spinal cord, the intimate connections of the top-down and
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Perspectivebottom-up pain system form a hierarchical recurrent model in
which the modulation related to placebo hypoalgesia is imple-
mented not at a single stage but throughout the system. Conse-
quently, our framework suggests a single system rather than
separate top-down and bottom-up systems. This is in agree-
ment with functional neuroimaging studies that have observed
pain modulatory signal changes at all levels of this system
(Amanzio et al., 2013; Wager et al., 2013), such as the spinal
cord (Eippert et al., 2009a), the PAG-RVM system (Bingel
et al., 2006; Eippert et al., 2009b; Petrovic et al., 2002; Tracey
et al., 2002; Wager et al., 2004; Yelle et al., 2009), the nucleus
cuneiformis (Keltner et al., 2006), the AMY (Bingel et al., 2006),
the rACC (Bantick et al., 2002; Bingel et al., 2006; Eippert
et al., 2009b; Geuter et al., 2013), THA (Lorenz et al., 2003; Valet
et al., 2004), and the PFC (Eippert et al., 2009b; Wager et al.,
2004).
The Mesolimbic System: Linking Value to Placebo
Hypoalgesia
Apart from the opioidergic system, several studies have linked
the dopaminergic (DA) system to placebo hypoalgesia using
MRI (Schweinhardt et al., 2009) or PET (Scott et al., 2007,
2008). DA is the main modulatory neurotransmitter in the meso-
limbic system including the substantia nigra, the ventral
tegmental area (VTA), the ventral striatum (VS), and frontal areas
such as the ventromedial prefrontal cortex (vmPFC). In the
context of a predictive coding framework, it has been proposed
that DA can signal the precision of predictions (Adams et al.,
2013; Edwards et al., 2012; Friston, 2010) in a similar manner
as we suggested for opioids in the PAG-RVM-spinal cord
system. Such a role of DA could also be involved in placebo hy-
poalgesia, as a study showed that individual expectations of
analgesia prior to placebo administration were correlated with
placebo-related DA activation in the VS (Scott et al., 2007). It is
conceivable that these expectation ratings also indicated the
volunteers’ confidence in the treatment, which can be seen in
analogy to the precision of the prediction (Brown et al., 2008).
In a study investigating opioidergic and dopaminergic effects
of placebo hypoalgesia (Scott et al., 2008), opioidergic and
dopaminergic effects were demonstrated in many subcortical
and cortical areas. In particular, in the VS both DA and opioider-
gic effects were observed. Based on this observation, the
authors suggest that VS dopaminergic responses represent a
‘‘trigger’’ that can then entail downstream adaptive responses.
These responses are most likely opioidergic, but dopaminergic
modulation of the dorsal horn has also been observed (Tamae
et al., 2005). Our model would offer a similar, yet simpler, expla-
nation: both opioids and DA as modulatory neurotransmitters
are ideally suited to signal the precision of predictions (Corlett
et al., 2009; Edwards et al., 2012; Friston, 2010). It is thus likely
that in some areas (e.g., the VS) they both signal the precision
of predictions, whereas in other areas (RVM-PAG system) opi-
oids more exclusively take this role, possibly together with
other neurotransmitters such as cannabinoids (Benedetti
et al., 2011). This is also in accord with recent experimental
data that suggest that at different levels of the hierarchy sepa-
rate neuromodulatory systems are related to precision-
weighted prediction errors (Iglesias et al., 2013). Importantly,
PET studies (Scott et al., 2008; Wager et al., 2007; Zubietaet al., 2005) suggest that opioids not only play a role in signaling
the precision of predictions in areas lower in the hierarchy as
compared to the VS but also in areas higher in the hierarchy
such as the rACC and the AI.
In the context of dopaminergic effects on placebo hypoalge-
sia, it has been discussed that projections between the vmPFC
and the VS play an important role in updating the effectiveness
of the treatment over time (Wager and Fields, 2013), which the
authors relate to subjective value of the treatment. Value in gen-
eral can be seen as an attribute for states and maximizing value
(or being in a valuable state) is the goal of the optimization
scheme underlying the free-energy principle (Friston, 2010), an
extension of the predictive coding framework. Minimizing free
energy in this framework is to ensure that organisms spend
most of their time in valuable states such as being satiated and
pain-free to maintain their homeostasis. This is conceptually
linked to reinforcement learning (Friston, 2010) and temporal
difference models and DA signaling (Schultz et al., 1997). In
essence, the idea is that neuronal value systems enable the brain
to label a sensory state as valuable, if it leads to another valuable
state. This ensures that agents move through a succession of
states (e.g., specific path in a maze) that have acquired value
to access states with an innate value (e.g., food). This notion
can be related to the desire-belief model of placebo hypoalgesia,
where it is argued that the overall desire of volunteers is to avoid
painful experience as much as possible (Price et al., 2008). It
should be noted that avoiding a painful experience ‘‘as much
as possible’’ is a relative rather than absolute concept of value,
as for example illustrated in a recent study showing that if a
painful stimulus is less painful than the maximally possible
painful stimulus, it can even be perceived as pleasant (Leknes
et al., 2013).
Furthermore, value can be an attribute of the treatment in
placebo hypoalgesia (Wager and Fields, 2013), rendering the
placebo effect more or less effective. This is best illustrated
through a behavioral study in which two different inert treatments
were tested (Waber et al., 2008). One treatment was described
as having a high monetary value (i.e., ‘‘regular price’’); the other
one was described as ‘‘low price.’’ This study convincingly
showed that the magnitude of placebo hypoalgesia was
increased for the ‘‘regular price’’ treatment. This behavioral
finding was followed up in an fMRI study (Geuter et al., 2013).
Here again one treatment was declared as low in value and
another one was described as high in value. Similar to a previous
study (Price et al., 1999), a congruent experience to these verbal
instructions was introduced in a conditioning phase, allowing
volunteers to experience the superior effect of the high-value
treatment. To directly assess the perceived individual value of
both treatments, volunteers participated in a typical auction
setup as used in behavioral economics to identify their willing-
ness-to-pay (WTP). Both experimental treatment creams (i.e.,
placebos) were presented alongside other useful medical prod-
ucts such as Band-Aids, sunscreen, or insect repellant. Impor-
tantly, it was observed that the estimated WTP predicted the
perceived pain reduction on an individual level. In addition, a
choice task analogous to the one used by Chib and colleagues
(2009) was performed to obtain a neuronal value signal
(Figure 2A). On a neuronal level, the rACC, during the placeboNeuron 81, March 19, 2014 ª2014 Elsevier Inc. 1229
Figure 2. Placebo-Induced BOLD Responses and Value Signal
Based on data reported in Geuter and colleagues (2013).
(A) Overlay of the placebo > control contrast (red; rACC p < 0.005; all p values small-volume corrected as reported in Geuter and colleagues (2013) and the WTP
correlate (blue; vmPFC p < 0.011; rACC p < 0.003; VS p < 0.003). WTP and placebo activation overlapped in the rACC (yellow; rACC p < 0.046).
(B) Correlation of placebo-induced activation (placebo > control) with the individual neural value estimates from vmPFC. Here, activity in the rACC correlated with
the value signal (p < 0.01). Statistical t-maps are overlaid on an average structural image at p < 0.005 (uncorrected).
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the expensive placebo treatment. In addition, the value-related
activation level of the vmPFC (ROI based on Chib et al., 2009)
during the valuation task was extracted. It was then tested
whether this neuronal value signal (from the valuation scan) pre-
dicted the placebo-related signals in the frontal cortex during the
placebo scan. Importantly, the placebo and the valuation scans
were performed in separate sessions. The data show that indeed
a neuronal value signal in the vmPFC was predictive of the pla-
cebo-related activation in the rACC (Figure 2B) or, in other
words, a neural signature of value-predicted activation related
to placebo hypoalgesia.
In some studies, naloxone had no effect on placebo hypoalge-
sia (Benedetti et al., 2011; Vase et al., 2005), suggesting that
other neurotransmitter systems also play a role. Even in studies
that report effects of high doses of naloxone, the opioid antago-
nist was only able to attenuate placebo hypoalgesia (Eippert
et al., 2009b), but not to completely block it. These observations
can be accounted for by our model. Given the hypothesis that
modulatory neurotransmitters signal the precision of the top-
down predictions in the proposed Bayesian framework, blocking
those neurotransmitters would not erase the prediction but
would attenuate its precision and thus lead to a decrease in
placebo hypoalgesia. However, as described above for the VS
in which both opioids and DA might play a role in signaling the
precision of a prediction, the precision signals in other areas
might be mediated by other modulatory neurotransmitters
such as oxytocin (Kessner et al., 2013b), cannabinoids (Bene-
detti et al., 2011), etc. This implementation would equip the
system with additional flexibility and redundancy and could
also account for the observed interindividual differences in
placebo responses and blocking them with various drugs. A
study employing the monetary incentive delay task (Knutson
et al., 2000) showed that individual responsiveness in the dopa-
minergic system during this task was predictive of the placebo
hypoalgesic effect (Scott et al., 2007). It is tempting to speculate
that volunteers showing a large contribution of dopaminergic
effects to placebo hypoalgesia would demonstrate a high vulner-
ability to a DA antagonist (e.g., haloperidol), whereas others
could be more naloxone sensitive. Further studies are required
to test the hypothesis that different individuals employ different1230 Neuron 81, March 19, 2014 ª2014 Elsevier Inc.modulatory neurotransmitter systems in placebo hypoalgesia.
Such a finding could potentially explain the large interindividual
differences that have been observed in this domain (Enck
et al., 2013).
Reporting Bias
Placebo effects (Hro´bjartsson and Gøtzsche, 2004) and placebo
hypoalgesia in particular (Clark, 1969) have been criticized to
simply reflect a reporting bias. Based on a study in which the
effects of placebo hypoalgesia were estimated using signal
detection theory, the authors argued that this analysis indicated
that the reduced number of pain responses in the placebo con-
dition reflected an increase in the amount of noxious stimulation
volunteers were willing to endure before calling it pain, rather
than a decrease in their thermal sensitivities (Clark, 1969).
Many years later it has been argued that providing direct central
nervous (Benedetti, 2013; Eippert et al., 2009b; Wager et al.,
2004) or autonomic (Eippert et al., 2009b; Nakamura et al.,
2012) measures in placebo studies can favor a sensory discrim-
ination effect and make an exclusive reporting bias unlikely. The
proposed hierarchical predictive coding framework takes amore
neutral position and would argue that the decision and the sen-
sory discrimination component are not separable in ameaningful
sense, or in other words, there is no clear point in a hierarchical
system where sensory processing ends and the decision pro-
cess begins; both the sensory perception and the decision
component are implemented throughout the hierarchy. In other
words, signal changes in both the spinal cord and the rACC
are probably responsible for what Clark (1969) describes as
‘‘. an increase in the amount of noxious stimulation Ss
[subjects] were willing to endure before calling it pain.’’
A Putative System
Converging anatomical data from rats, cats, and monkeys sug-
gests a strong degree of reciprocity in the connectional architec-
ture of the ‘‘descending system,’’ as evidenced between spinal
cord and RVM (Basbaum and Fields, 1979; Basbaum et al.,
1978; Carlton et al., 1985; Craig, 1995; Sugiyo et al., 2005),
RVM and PAG (Abols and Basbaum, 1981; Basbaum et al.,
1976; Beitz, 1982a, 1982b; Mantyh, 1982, 1983a), PAG and
AMY (Aggleton et al., 1980; Beitz, 1982b; Hopkins and Holstege,
1978; Mantyh, 1983b; Rizvi et al., 1991; Volz et al., 1990), PAG
and HT (Aimone et al., 1988; Cameron et al., 1995; Mantyh,
Figure 3. A Putative System Mediating Placebo Hypoalgesia
Note the recurrent nature of all connections in the hypothetical system
(simplified by omitting several connections and areas). Whereas the cortical
and subcortical projections all converge onto the PAG-RVM-spinal cord sys-
tem, there are many cortical systems potentially mediating different aspects of
placebo hypoalgesia. For instance, the projections from the rACC to the PAG
(green) might resemble expectation effects in a more general fashion, whereas
the projections from the vmPFC and the HT (red) might mediate the value
aspect of placebo hypoalgesia.
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Perspective1982, 1983b; Sakai et al., 1990), AMY and AI and rACC/vmPFC
(Aggleton et al., 1980; Carmichael and Price, 1995; Krettek and
Price, 1977; Mcdonald et al., 1996; Mufson et al., 1981;
Russchen, 1982), as well as HT and AI and rACC/vmPFC (Floyd
et al., 2001; Jasmin et al., 2004; Kita and Oomura, 1981; Mesu-
lam et al., 1983; Musil and Olson, 1988; Ongu¨r et al., 1998; Room
et al., 1985); note that due to brevity, we are not discussing all
projections (such as direct ones between rACC/vmPFC and
PAG) here. There are only very few exceptions to this reciprocity,
such as rather light connections from the dorsal horn of the
spinal cord to the RVM (Lima, 2009; but these could for example
be compensated by spinal input to PAG and HT: Dostrovsky and
Craig, 2013; Lima, 2009) or inconclusive evidence for reciprocal
connections between HT and AI in the cat.
The notion of a recurrent hierarchical model also shifts the
focus from the analysis of regional activity toward the analysis
of interregional effects. In agreement with this notion, many
studies have consistently observed placebo hypoalgesia-related
changes of functional coupling in human functional neuroimag-
ing studies (Bingel et al., 2006; Craggs et al., 2007; Petrovic
et al., 2002; Wager et al., 2007). The interregional coupling
between the rACC and the PAG was found to be increased dur-
ing placebo hypoalgesia (Bingel et al., 2006; Petrovic et al., 2002;
Wager et al., 2007). Furthermore, this increased coupling was
attenuated by naloxone and furthermore correlated to behavioral
reports of hypoalgesia and activation changes in sensory-related
pain-processing areas (SII) (Eippert et al., 2009b).
As placebo hypoalgesia is subject to numerous influences
such as expectations, motivations, and emotions (Price et al.,2008), such a system might implement these modulatory effects
in a parsimonious fashion, by drawing upon different cortical
ensembles for different modulatory effects, but at the same
time utilize a final common pathway such as the PAG-RVM-
spinal cord system (Figure 3). This notion is supported by a
comprehensive network analysis study (Wager et al., 2007). In
this data set, an increase of opioid release in rACC, PAG, VTA,
VS, and AMY was seen for heat stimuli only, whereas the lateral
PFC, AI, and the AMY showed decreases to warm stimuli. The
authors concluded that the mechanism for areas that only
respond to heat stimuli is the potentiation of opioid release,
whereas decreases that are related to warm stimuli could be
related to the reduction of anticipatory threat. Our framework
would offer a slightly different interpretation: the increase in
opioid release would be related to signaling predictions along
the rACC-PAG system, whereas the decreases of opioidergic
release in AMY and AI would be related to signaling predictions
of decreased threat (Lundh, 1987; Price et al., 2008).
Placebo effects have also been explained by referring to a
desire expectation model of emotions (Price and Barrell, 1984;
Price et al., 2008). In addition to simpler models relying mainly
on expectations, this model adds a desire component implying
that in analgesia studies, volunteers have the desire to terminate
pain. Previous studies have shown that the interaction of ‘‘desire
for pain relief’’ and ‘‘expected pain relief’’ contributes sig-
nificantly to placebo hypoalgesia. The model further predicts a
parallel decrease of negative emotions, which has been
observed behaviorally (Vase et al., 2003; Verne et al., 2003)
and has been suggested by fMRI studies showing signal
changes in areas implicated in anxiety and emotion regulation
in placebo hypoalgesia studies (Bingel et al., 2006; Price et al.,
2008; Wager et al., 2011).
The role of negative emotions in mechanisms of the placebo
effect is also part of a cognitive-emotion model (Flaten et al.,
2011; Lundh, 1987). Here, it is argued that illness often involves
negative psychological aspects such as anxiety, sadness, or
depression and an important part of the placebo effect is the
development of ‘‘healing’’ beliefs. These beliefs are thought to
counteract negative psychological aspects and thus have a
positive influence on physical health (i.e., pain in placebo hypo-
algesia). Conceptually, these cognitive-emotion models are in
agreement with a hierarchical Bayesian model of placebo hypo-
algesia. Althoughwe initially explained the idea of suchmodels in
a single chain of recurrent brain areas (i.e., rACC-PAG-RVM-
spinal cord), this system is more complex, as many regions are
not only connected to areas up or down in the hierarchy, but
rather to other areas (Figure 3). This suggests that top-down pre-
dictions in this framework do not only originate from a single area
higher up in the hierarchy but from many regions (e.g., AI, rACC,
and AMY) converging on lower tier structures (and vice versa)
(Adams et al., 2013). Many cortical and subcortical regions
such as the AI, the rACC, the AMY, and the HT have recurrent
connections with the PAG. It is thus possible that the manifold
of contextual effects that are part of most psychological theories
of placebo hypoalgesia (Flaten et al., 2011; Lundh, 1987; Price
et al., 2008) such as anxiety reduction, emotions, beliefs, and
desire are mediated by overlapping projections in this system.
For instance, AMY and AI might be involved in signalingNeuron 81, March 19, 2014 ª2014 Elsevier Inc. 1231
Figure 4. Predictions from the Bayesian
Framework for Different Magnitudes and
Precisions of the Prior Expectation in
Placebo Hypoalgesia Experiments
The red Gaussian distribution characterizes the
prediction (e.g., expectation; prior). Both different
magnitudes (A and B versus C and D) and pre-
cisions (A and C versus B and D) are implemented.
The blue Gaussian distribution characterizes the
incoming sensory data (constant across condi-
tions; likelihood). Based on the Gaussian model
this leads to the posterior distribution (green) that
resembles the placebo effect.
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Perspectivefear-related predictions (Figure 3, gray), whereas the vmPFC and
HT might mediate predictions with respect to value or desire
(Figure 3, red).
Predictions
TheproposedBayesian frameworkmakes certainbehavioral pre-
dictions that can be tested experimentally. Importantly, all these
approaches have in common that the precision and the magni-
tude of either the prediction or the incoming sensory signals is
varied independently. Only this allows testing crucial predictions
from themodel such as (1) how the precision of the prediction and
the data affect placebo hypoalgesia, evenwhen themagnitude is
kept constant, and (2) how the precision of the prediction ismedi-
ated by modulatory neurotransmitter systems such as dopamine
and opioids. Figure 4 summarizes these hypotheses in an exper-
iment in which the precision of the placebo manipulation (e.g.,
previous experience or expectation) is varied. As there might be
interactions between differences in magnitude and variability of
the prediction, a full factorial 23 2 design is depicted.
Intuitively, all distributions can be interpreted as ‘‘approxi-
mated histograms,’’ e.g., in conditions A and B the average
expectation is about 40 on a VAS, whereas it is 50 in conditions
C and D. The width of the distribution indicates the variability
(low precision in B and D as compared to A and C. The distribu-
tion of the painful stimulation with a mean of VAS 60 is identical
for all conditions. According to our framework, high expectation
with high precision should lead to the strongest placebo
response (green posterior distribution in A), whereas a low
expectation with low precision should lead to the weakest pla-
cebo response (green posterior distribution in D). As outlined
above, this manipulation will have a limit, namely when the
expectation (prior) is ‘‘too far away’’ from the incoming data (like-1232 Neuron 81, March 19, 2014 ª2014 Elsevier Inc.lihood). This would lead to a dramatic
revisiting of the model to explain the
incoming data, i.e., the initial model of a
treatment reducing pain would be
replaced by a model that entails a decep-
tion (i.e., no treatment).
Conversely, one could manipulate the
magnitude and the precision of the
incoming sensory data. This is relevant,
as in clinical conditions such as IBS or
fibromyalgia the precision of the sensory
signal (i.e., ongoing pain) might be more
variable as compared to well-definedexperimental pain stimuli. In this 2 3 2 design (Figure 5), the
expectation (red) is kept constant across conditions. However,
now the incoming sensory stimulus (blue) is varied in magnitude
(i.e., intensity: A and B versus C and D or precision: A and C
versus B and D. According to the presentedmodel, the strongest
placebo hypoalgesic effect should be obtained with a highly var-
iable painful stimulus (low precision; green posterior in B and D.
On a related account, a meta-analysis has shown that a longer
stimulus duration can result in a larger magnitude of placebo
hypoalgesia (Vase et al., 2009). This could be due to a higher
variability (i.e., lower precision) of average perception of longer
stimuli, as volunteers have to integrate pain sensations over a
longer time period. In future studies, it would be useful to obtain
continuous ratings of perceived pain in paradigms with longer
painful stimulation in order to assess the variability and to allow
further model-based analyses (Cecchi et al., 2012).
Predictions for Population-Based Neuronal Data
Many studies have revealed behavioral evidence for predictive
coding schemes (Clark, 2013; Knill and Pouget, 2004). Conse-
quently, it would be interesting to reveal a possible neuronal
implementation of this framework (O’Reilly et al., 2012). Using
fMRI or other population-based techniques for this endeavor is
not trivial, because both the top-down prediction and the
bottom-up prediction error will contribute to the observed signal
changes in such an area. The matter is further complicated by
the fact that one cannot assume a simple 1:1 contribution of
both processes (Egner et al., 2010).
However, a finessed experimental design might allow some
inferences about the interplay between prediction and prediction
errors, which would suggest a predictive coding framework in
the context of pain. In analogy with Egner and colleagues
(2010), one could employ a painful and a nonpainful hot stimulus
Figure 5. Predictions from the Bayesian
Framework for Different Magnitudes and
Precisions of the Incoming Sensory
Information in Placebo Hypoalgesia
Experiments
The blue Gaussian distribution characterizes the
incoming sensory data (likelihood). Both different
magnitudes (A and B versus C and D) and pre-
cisions (A and C versus B and D) are implemented.
The red Gaussian distribution characterizes the
prediction (e.g., expectation), which is kept con-
stant across conditions. Based on the Bayesian
model, this leads to the posterior distribution
(green) that resembles the effect of the placebo
manipulation.
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cortical region that shows nociceptive-specific responses, such
as the posterior insula (Garcia-Larrea, 2012; Mazzola et al.,
2012), should show a constant response to all painful stimuli irre-Neuron 81spective of the expectation of pain. On
the contrary, for hot stimuli the activity in
this area should be dependent on the
level of pain expectation. This distinction
comes about because the response to
the painful stimulus is a combination of
prediction error or surprise (higher activa-
tion with low expectation; Figure 6A; see
also Ploghaus et al., 2000 for an early
study on prediction errors in the context
of pain) and prediction (higher with high
expectation; Figure 6B), leading to a con-stant response across expectation levels (Figure 6C). In contrast,
nonpainful hot stimuli should lead to an increase in activation
with increasing pain expectation. Importantly, if the assumption
of pain specificity is violated (i.e., the region in question alsoFigure 6. Predictions for Regional Activity
Changes in a Predictive Coding Framework
Based on Egner et al. (2010).
(A) For a painful stimulus and a nonpainful stim-
ulus, the signal component due to prediction
increases with the expectation of pain.
(B) In contrast, the signal component due to
surprise decreases with increasing prediction but
only for the painful stimulus.
(C) Based on the sum of (A) and (B), an area
involved in a predictive coding scheme should
show a relatively constant activation for a painful
stimulus and at the same time an increase for a
nonpainful hot stimulus with increasing pain
expectation. Note that in case of an area that re-
sponds equally well to pain and nonpainful hot
stimuli, the response pattern for both should be
identical.
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Perspectiveresponds to nonpainful hot stimuli), the ensuing activation
pattern would not wrongly suggest a predictive coding frame-
work but simply show identical activation levels for pain and non-
painful hot stimuli (i.e., equal activation levels in Figure 6C). In
addition, this experimental design could be adapted to a phar-
macological fMRI study that would allow investigating the role
of the dopaminergic and opioidergic system in the hypothesized
effects.
Ongoing Activity
In a perceptual decision making study Hesselmann and
colleagues (2010) observed that fluctuations in ongoing neural
activity, as indexed by fMRI, biased perceptual decisions toward
correct inference but not toward a specific percept: hits (detec-
tion of near-threshold stimuli) were preceded by significantly
higher activity than both misses and false alarms. Based on
this observation, they concluded that the observed activity prob-
ably corresponds to the precision of later-occurring prediction
errors (see also Coste et al., 2011).
Translated into the context of our predictive coding framework
for placebo hypoalgesia, we would predict that prestimulus ac-
tivity fluctuations, e.g., in the PAG, are related to the placebo hy-
poalgesic effect. This seems plausible, as a previous study has
already demonstrated the negative predictive value of prestimu-
lus PAG activity for pain perception (Ploner et al., 2010; see also
Brodersen et al., 2012). Furthermore, if the hypothesis that pre-
cision is mediated by opioidergic signaling in this system is cor-
rect, we would expect that the predictive value of prestimulus
activity is not related to placebo hypoalgesia if volunteers were
treated with an opioid antagonist.
Conclusion
Here we have taken a Bayesian perspective on placebo hypo-
algesia and have aimed to explain fundamental findings in
terms of a hierarchical neurobiological model based on the
framework of predictive coding. We have applied this frame-
work only to placebo hypoalgesia and in some cases to expec-
tation-induced modulation of acute pain in healthy volunteers,
leaving aside important topics such as central sensitization
and pathophysiological (Woolf, 2011) or psychological pro-
cesses in chronic pain patients (Morley, 2008). It will be an
exciting endeavor to see how the ideas developed here and
extensions thereof can be applied to clinical populations
(Edwards et al., 2012).
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